PursueCare Revives FDA-Approved Digital Therapeutics for Addiction Treatment
核心洞察
PursueCare (搜索) has successfully acquired and relaunched RESET and RESET-O, two FDA-approved digital therapeutics for addiction treatment, following Pear Therapeutics (搜索)' bankruptcy in 2023.
The digital therapeutics deliver 12-week cognitive behavioral therapy programs, helping patients identify and manage addiction triggers, with RESET targeting multiple substances and RESET-O specifically designed for opioid addiction.
PursueCare (搜索) plans to integrate these clinically-proven applications into their telehealth addiction treatment programs across nine states, with future plans to expand availability to other healthcare providers.
PursueCare (搜索) has breathed new life into two groundbreaking digital therapeutics (DTx) for addiction treatment, acquiring the FDA-approved applications RESET and RESET-O from the dissolved Pear Therapeutics (搜索) portfolio. The acquisition marks a significant development in the digital health landscape, particularly for addiction medicine.
Digital Therapeutic Applications and Clinical Impact
The cornerstone of these digital interventions is a 12-week cognitive behavioral therapy (CBT) program. RESET, which made history in 2017 as the FDA's first approved software-only therapeutic, addresses multiple substance dependencies including alcohol, cocaine, marijuana, and stimulants. Its companion application, RESET-O, received FDA approval in 2018 specifically for opioid use disorder (搜索) treatment.
Clinical data supports the efficacy of these digital therapeutics, demonstrating improved treatment retention rates across both applications. RESET has shown particular promise in enhancing abstinence rates among users, suggesting significant potential for improving addiction treatment outcomes.
Integration with Telehealth Services
PursueCare (搜索), operating across nine states in the US, specializes in delivering personalized addiction treatment through telehealth platforms. The company's smartphone-based care delivery model aligns naturally with these digital therapeutic solutions, creating an integrated approach to addiction treatment.
Nick Mercadante, PursueCare (搜索)'s founder and CEO, emphasized the company's mission: "We are driven by the belief that everyone deserves accessible, high-quality care that meets them where they are and stays with them through their journey. Digital therapeutics empower individuals to reclaim control over their health, advancing a new standard of care for chronic substance use disorder (搜索)."
Business Strategy and Future Plans
The acquisition occurred through a multi-step process, with Harvest Bio (搜索) initially purchasing the applications for approximately $2 million during Pear Therapeutics (搜索)' bankruptcy proceedings. PursueCare (搜索) subsequently acquired the applications in December, coinciding with a $20 million fundraising round.
While PursueCare (搜索) will initially incorporate RESET and RESET-O into their existing treatment programs, they plan to expand availability to other healthcare providers. The company maintains that these digital therapeutics have demonstrated capacity to reduce substance use, increase treatment retention, and lower overall healthcare costs.
Market Context and Industry Impact
The revival of these digital therapeutics comes at a crucial time in addiction medicine. While Pear Therapeutics (搜索) struggled with securing reimbursement for digital therapeutic treatments in the US healthcare system, PursueCare (搜索)'s established presence in telehealth addiction treatment may provide a more sustainable pathway for these innovative tools.
This development represents a significant milestone in the digital health sector, potentially setting new precedents for how digital therapeutics can be successfully integrated into existing healthcare delivery models.